{ "run": { "id": "cmnr12b4601z0p658790b6ncq", "region": "US", "assetId": "cmnr12b3l01ywp6585qoz4q81", "ticker": "ALGN", "snapshotId": "cmnr12b3t01yyp658iik5ebkr", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:19:37.924Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr12b3t01yyp658iik5ebkr", "assetId": "cmnr12b3l01ywp6585qoz4q81", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 176.83, "dayLow": 176, "volume": 898776, "dayHigh": 185, "currency": "USD", "prevClose": 166.87, "week52Low": 122, "week52High": 208.31 }, "fundamentals": { "pe": 27.5883392226148, "beta": 1.54857516143291, "epsTTM": 5.66, "fcfTTM": 495468000, "growth": { "epsYoy": 0.005328596802841963, "revenueYoy": 0.008990220584484367 }, "sector": "Orthopedic, Prosthetic & Surgical Appliances & Supplies", "margins": { "net": 0.1016988007823614, "gross": 0.6718803439138491, "operating": 0.1352564731680382 }, "website": "https://aligntech.com", "industry": "Orthodontics", "pegRatio": 51.7741166077727, "ebitdaTTM": 782540000, "forwardPe": 17.1971365638767, "marketCap": 11100000000, "totalCash": 1094908000, "totalDebt": null, "debtEquity": null, "quickRatio": 0.5952078499386724, "revenueTTM": 4034964000, "companyName": "ALIGN TECHNOLOGY INC", "priceToBook": 2.79748631007963, "currentRatio": 1.362782061598477, "dividendYield": null, "returnOnAssets": 0.0658279129241687, "returnOnEquity": 0.101342579066653, "analystOpinions": null, "businessSummary": "Align Technology, Inc. is an American manufacturer of 3D digital scanners and Invisalign clear aligners used in orthodontics and restorative workflow. It was founded in 1997 and is headquartered in Tempe, Arizona. The company manufactures the aligners in Juarez, Mexico, and its scanners in Israel and China. The company is best known for its Invisalign system, which is a clear aligner treatment used to straighten teeth.", "enterpriseValue": null, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 20945, "sharesOutstanding": 71282132, "enterpriseToEbitda": null, "analystTargetMedian": null, "enterpriseToRevenue": null, "operatingCashflowTTM": 593223000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:19:37.913Z" }, "results": [ { "id": "cmnr12b4d01z2p658ronqf2le", "runId": "cmnr12b4601z0p658790b6ncq", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"ALGN\",\"currency\":\"USD\",\"current_price\":176.83,\"target_price_6m\":180,\"target_price_12m\":182,\"recommendation\":\"HOLD\",\"confidence\":0.52,\"thesis_bullets\":[\"Near-zero revenue and EPS growth limits re-rating catalysts near-term\",\"Strong gross margins (~67%) but operating margins compressed at 13.5%\",\"Healthy FCF yield ~4.5% and $1.1B cash with no listed debt\",\"Forward P/E 17.2x implies steep earnings recovery still unproven\",\"High PEG ratio of 51.8 signals poor growth-to-valuation trade-off\"],\"key_drivers\":[{\"driver\":\"Invisalign volume growth recovery in developed markets\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International expansion especially in APAC\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin leverage from scale and cost optimization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"iTero scanner upgrade cycle driving recurring revenue\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Consumer discretionary spending pressures on elective dental\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Increasing competition from generic clear aligner players\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Foreign currency headwinds given global revenue mix\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Tariff exposure on manufacturing in Mexico and China\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Sustained macro weakness reduces consumer willingness to pay for elective orthodontics\",\"Generic clear aligner competition compresses pricing and share\",\"Regulatory changes in key international markets slow adoption\",\"Forward EPS expectations prove too aggressive causing multiple contraction\",\"Trade/tariff escalation on Mexico and China manufacturing hubs\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.19,\"wacc\":0.105,\"terminal_multiple\":22},\"scenarios\":{\"bear\":{\"target_price\":145,\"prob\":0.25,\"notes\":\"Growth stays flat, margins compress, multiple contracts to ~15x.\"},\"base\":{\"target_price\":182,\"prob\":0.55,\"notes\":\"Modest revenue recovery with gradual margin expansion to mid-teens operating.\"},\"bull\":{\"target_price\":210,\"prob\":0.20,\"notes\":\"Volume inflects higher, margin leverage emerges, multiple re-rates to ~22x.\"}},\"method_notes\":\"Blended EV/EBIT and forward P/E approach using snapshot fundamentals. Revenue CAGR 6% assumes gradual recovery from near-zero current growth. Weighted scenario return ~0.9%, consistent with HOLD. PEG >50 and sub-1% YoY growth create limited upside conviction despite strong balance sheet. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Sustained macro weakness reduces consumer willingness to pay for elective orthodontics", "Generic clear aligner competition compresses pricing and share", "Regulatory changes in key international markets slow adoption", "Forward EPS expectations prove too aggressive causing multiple contraction", "Trade/tariff escalation on Mexico and China manufacturing hubs" ], "ticker": "ALGN", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Modest revenue recovery with gradual margin expansion to mid-teens operating.", "target_price": 182 }, "bear": { "prob": 0.25, "notes": "Growth stays flat, margins compress, multiple contracts to ~15x.", "target_price": 145 }, "bull": { "prob": 0.2, "notes": "Volume inflects higher, margin leverage emerges, multiple re-rates to ~22x.", "target_price": 210 } }, "confidence": 0.52, "assumptions": { "wacc": 0.105, "revenue_cagr_3y": 0.06, "terminal_multiple": 22, "ebit_margin_target": 0.19 }, "key_drivers": [ { "driver": "Invisalign volume growth recovery in developed markets", "impact": "HIGH", "direction": "POS" }, { "driver": "International expansion especially in APAC", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin leverage from scale and cost optimization", "impact": "MED", "direction": "POS" }, { "driver": "iTero scanner upgrade cycle driving recurring revenue", "impact": "MED", "direction": "POS" }, { "driver": "Consumer discretionary spending pressures on elective dental", "impact": "HIGH", "direction": "NEG" }, { "driver": "Increasing competition from generic clear aligner players", "impact": "MED", "direction": "NEG" }, { "driver": "Foreign currency headwinds given global revenue mix", "impact": "MED", "direction": "NEG" }, { "driver": "Tariff exposure on manufacturing in Mexico and China", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended EV/EBIT and forward P/E approach using snapshot fundamentals. Revenue CAGR 6% assumes gradual recovery from near-zero current growth. Weighted scenario return ~0.9%, consistent with HOLD. PEG >50 and sub-1% YoY growth create limited upside conviction despite strong balance sheet. Not investment advice.", "current_price": 176.83, "recommendation": "HOLD", "thesis_bullets": [ "Near-zero revenue and EPS growth limits re-rating catalysts near-term", "Strong gross margins (~67%) but operating margins compressed at 13.5%", "Healthy FCF yield ~4.5% and $1.1B cash with no listed debt", "Forward P/E 17.2x implies steep earnings recovery still unproven", "High PEG ratio of 51.8 signals poor growth-to-valuation trade-off" ], "target_price_6m": 180, "target_price_12m": 182 }, "errorsJson": { "attempts": [ { "error": "sanity_error: hold_scenario_return_too_directional: HOLD requires probability-weighted scenario return within +/-6%.", "attempt": 0, "rawOutputTruncated": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"ALGN\",\"currency\":\"USD\",\"current_price\":176.83,\"target_price_6m\":182,\"target_price_12m\":186,\"recommendation\":\"HOLD\",\"confidence\":0.52,\"thesis_bullets\":[\"Near-zero revenue and EPS growth limits re-rating catalysts near-term\",\"Strong gross margins (~67%) but operating margins compressed at 13.5%\",\"Healthy FCF yield of ~4.5% and $1.1B cash with no listed debt\",\"Forward P/E of 17.2x implies steep earnings recovery that remains unproven\",\"High PEG ratio of 51.8 signals poor growth-to-valuation trade-off currently\"],\"key_drivers\":[{\"driver\":\"Invisalign volume growth recovery in developed markets\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International expansion especially in APAC\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin leverage from scale and cost optimization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"iTero scanner upgrade cycle driving recurring revenue\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Consumer discretionary spending pressures on elective dental\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Increasing competition from SmileDirectClub successors and generics\",\"impact…" } ], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 58929, "createdAt": "2026-04-09T05:19:37.924Z", "usage": { "inputTokens": 4185, "outputTokens": 1145, "costUsd": 0.04955 } }, { "id": "cmnr12b4d01z5p658m4rlyy37", "runId": "cmnr12b4601z0p658790b6ncq", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Research_Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"ALGN\",\n \"currency\": \"USD\",\n \"current_price\": 176.83,\n \"target_price_6m\": 165,\n \"target_price_12m\": 160,\n \"recommendation\": \"SELL\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Low recent EPS and revenue growth indicating maturity.\",\n \"High P/E and PEG ratio suggest overvaluation.\",\n \"Forward P/E lower but still premium to growth rates.\",\n \"Increasing competition in clear aligner market.\",\n \"Limited near-term catalysts for positive re-rating.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue Growth\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Margin Pressure\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Market Competition\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Innovation Cycle\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Economic Sensitivity\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"International Expansion\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory Environment\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Customer Adoption Rates\", \"impact\": \"HIGH\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Intensifying competition from new entrants.\",\n \"Economic downturn affecting discretionary spending.\",\n \"Technological disruption in orthodontics.\",\n \"Execution risks in new product launches.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.135,\n \"wacc\": 0.09,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 140, \"prob\": 0.3, \"notes\": \"Growth stalls and multiples contract further.\" },\n \"base\": { \"target_price\": 160, \"prob\": 0.5, \"notes\": \"Steady low growth with maintained margins.\" },\n \"bull\": { \"target_price\": 190, \"prob\": 0.2, \"notes\": \"Upside from market share gains and innovation.\" }\n },\n \"method_notes\": \"Valuation based on forward P/E and growth assumptions; SELL due to high valuation vs low growth. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI_Equity_Research_Model", "risks": [ "Intensifying competition from new entrants.", "Economic downturn affecting discretionary spending.", "Technological disruption in orthodontics.", "Execution risks in new product launches." ], "ticker": "ALGN", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady low growth with maintained margins.", "target_price": 160 }, "bear": { "prob": 0.3, "notes": "Growth stalls and multiples contract further.", "target_price": 140 }, "bull": { "prob": 0.2, "notes": "Upside from market share gains and innovation.", "target_price": 190 } }, "confidence": 0.6, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.05, "terminal_multiple": 15, "ebit_margin_target": 0.135 }, "key_drivers": [ { "driver": "Revenue Growth", "impact": "LOW", "direction": "NEG" }, { "driver": "Margin Pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Market Competition", "impact": "HIGH", "direction": "NEG" }, { "driver": "Innovation Cycle", "impact": "MED", "direction": "POS" }, { "driver": "Economic Sensitivity", "impact": "LOW", "direction": "NEG" }, { "driver": "International Expansion", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory Environment", "impact": "LOW", "direction": "NEG" }, { "driver": "Customer Adoption Rates", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Valuation based on forward P/E and growth assumptions; SELL due to high valuation vs low growth. Not investment advice.", "current_price": 176.83, "recommendation": "SELL", "thesis_bullets": [ "Low recent EPS and revenue growth indicating maturity.", "High P/E and PEG ratio suggest overvaluation.", "Forward P/E lower but still premium to growth rates.", "Increasing competition in clear aligner market.", "Limited near-term catalysts for positive re-rating." ], "target_price_6m": 165, "target_price_12m": 160 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 356, "createdAt": "2026-04-09T05:19:37.924Z", "usage": { "inputTokens": 2091, "outputTokens": 4975, "costUsd": 0.002675 } }, { "id": "cmnr12b4d01z3p6580sjiiqm7", "runId": "cmnr12b4601z0p658790b6ncq", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"ALGN_DCF_Multiples_Blended\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"ALGN\",\n \"currency\": \"USD\",\n \"current_price\": 176.83,\n \"target_price_6m\": 178.00,\n \"target_price_12m\": 182.00,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Revenue growth has stalled at under 1% YoY due to weak discretionary consumer spending.\",\n \"Forward P/E of 17.2x appears cheap but relies on an aggressive earnings recovery.\",\n \"Strong balance sheet with $1.09B cash provides downside protection and buyback optionality.\",\n \"Competition in the clear aligner market limits pricing power and margin expansion.\",\n \"Macroeconomic headwinds in key markets continue to delay adult orthodontic case starts.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Consumer Discretionary Spending\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Adult Case Volumes\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Teen Orthodontic Market Penetration\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"iTero Scanner Upgrades\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"International Market Expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"ASP (Average Selling Price) Trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating Margin Leverage\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged inflation reducing demand for premium aesthetic dental procedures.\",\n \"Increased competition from Envista (Spark) and direct-to-consumer alternatives.\",\n \"Foreign exchange headwinds impacting international revenue realization.\",\n \"Failure to achieve the aggressive EPS growth implied by forward estimates.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.18,\n \"wacc\": 0.095,\n \"terminal_multiple\": 18.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 135.00,\n \"prob\": 0.30,\n \"notes\": \"Recessionary pressures cause case volumes to contract, compressing margins and multiple to 14x.\"\n },\n \"base\": {\n \"target_price\": 182.00,\n \"prob\": 0.50,\n \"notes\": \"Modest volume recovery in H2 offsets near-term macro headwinds, achieving 18x forward P/E.\"\n },\n \"bull\": {\n \"target_price\": 230.00,\n \"prob\": 0.20,\n \"notes\": \"Consumer confidence rebounds sharply, driving double-digit teen and adult case growth.\"\n }\n },\n \"method_notes\": \"Blended valuation using 10-year DCF (9.5% WACC) and 18x target P/E on NTM earnings. Near-term macro headwinds constrain upside, justifying a HOLD recommendation. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ALGN_DCF_Multiples_Blended", "risks": [ "Prolonged inflation reducing demand for premium aesthetic dental procedures.", "Increased competition from Envista (Spark) and direct-to-consumer alternatives.", "Foreign exchange headwinds impacting international revenue realization.", "Failure to achieve the aggressive EPS growth implied by forward estimates." ], "ticker": "ALGN", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Modest volume recovery in H2 offsets near-term macro headwinds, achieving 18x forward P/E.", "target_price": 182 }, "bear": { "prob": 0.3, "notes": "Recessionary pressures cause case volumes to contract, compressing margins and multiple to 14x.", "target_price": 135 }, "bull": { "prob": 0.2, "notes": "Consumer confidence rebounds sharply, driving double-digit teen and adult case growth.", "target_price": 230 } }, "confidence": 0.65, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.04, "terminal_multiple": 18, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "Consumer Discretionary Spending", "impact": "HIGH", "direction": "NEG" }, { "driver": "Adult Case Volumes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Teen Orthodontic Market Penetration", "impact": "MED", "direction": "POS" }, { "driver": "iTero Scanner Upgrades", "impact": "MED", "direction": "POS" }, { "driver": "International Market Expansion", "impact": "MED", "direction": "POS" }, { "driver": "ASP (Average Selling Price) Trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operating Margin Leverage", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended valuation using 10-year DCF (9.5% WACC) and 18x target P/E on NTM earnings. Near-term macro headwinds constrain upside, justifying a HOLD recommendation. Not investment advice.", "current_price": 176.83, "recommendation": "HOLD", "thesis_bullets": [ "Revenue growth has stalled at under 1% YoY due to weak discretionary consumer spending.", "Forward P/E of 17.2x appears cheap but relies on an aggressive earnings recovery.", "Strong balance sheet with $1.09B cash provides downside protection and buyback optionality.", "Competition in the clear aligner market limits pricing power and margin expansion.", "Macroeconomic headwinds in key markets continue to delay adult orthodontic case starts." ], "target_price_6m": 178, "target_price_12m": 182 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 26889, "createdAt": "2026-04-09T05:19:37.924Z", "usage": { "inputTokens": 2389, "outputTokens": 891, "costUsd": 0.01547 } }, { "id": "cmnr12b4d01z1p658y4h9kohx", "runId": "cmnr12b4601z0p658790b6ncq", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"gpt-5\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"ALGN\",\"currency\":\"USD\",\"current_price\":176.83,\"target_price_6m\":172,\"target_price_12m\":184,\"recommendation\":\"HOLD\",\"confidence\":0.62,\"thesis_bullets\":[\"Invisalign remains the clear-aligner leader with strong gross margins.\",\"Recent revenue and EPS growth are muted, limiting rerating potential.\",\"Net cash and healthy free cash flow support downside resilience.\",\"Valuation looks reasonable, but upside needs clearer volume recovery.\",\"Modest margin improvement can offset only moderate top-line growth.\"],\"key_drivers\":[{\"driver\":\"Invisalign case volume recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Consumer dental spending softness\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"iTero scanner placements\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"International penetration\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Gross margin stability\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating expense discipline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Competitive pricing pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"FX and manufacturing concentration\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Prolonged orthodontic demand weakness\",\"Competitive pricing compresses margins\",\"Scanner adoption slows further\",\"Manufacturing or supply disruptions\",\"Macro-driven consumer deferrals\"],\"assumptions\":{\"revenue_cagr_3y\":0.07,\"ebit_margin_target\":0.17,\"wacc\":0.1,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":145,\"prob\":0.25,\"notes\":\"Demand stays soft and margin recovery stalls.\"},\"base\":{\"target_price\":184,\"prob\":0.5,\"notes\":\"Cases improve gradually and margins recover modestly.\"},\"bull\":{\"target_price\":225,\"prob\":0.25,\"notes\":\"Case growth reaccelerates and operating leverage returns.\"}},\"method_notes\":\"Base target uses blended EV/EBIT and normalized earnings anchored to snapshot fundamentals, adding net cash. Snapshot quote fields were kept authoritative; no sell-side price targets used as inputs. HOLD fits ~4% 12M upside with mixed growth and demand evidence. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "gpt-5", "risks": [ "Prolonged orthodontic demand weakness", "Competitive pricing compresses margins", "Scanner adoption slows further", "Manufacturing or supply disruptions", "Macro-driven consumer deferrals" ], "ticker": "ALGN", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Cases improve gradually and margins recover modestly.", "target_price": 184 }, "bear": { "prob": 0.25, "notes": "Demand stays soft and margin recovery stalls.", "target_price": 145 }, "bull": { "prob": 0.25, "notes": "Case growth reaccelerates and operating leverage returns.", "target_price": 225 } }, "confidence": 0.62, "assumptions": { "wacc": 0.1, "revenue_cagr_3y": 0.07, "terminal_multiple": 18, "ebit_margin_target": 0.17 }, "key_drivers": [ { "driver": "Invisalign case volume recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Consumer dental spending softness", "impact": "HIGH", "direction": "NEG" }, { "driver": "iTero scanner placements", "impact": "MED", "direction": "POS" }, { "driver": "International penetration", "impact": "MED", "direction": "POS" }, { "driver": "Gross margin stability", "impact": "MED", "direction": "POS" }, { "driver": "Operating expense discipline", "impact": "MED", "direction": "POS" }, { "driver": "Competitive pricing pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "FX and manufacturing concentration", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Base target uses blended EV/EBIT and normalized earnings anchored to snapshot fundamentals, adding net cash. Snapshot quote fields were kept authoritative; no sell-side price targets used as inputs. HOLD fits ~4% 12M upside with mixed growth and demand evidence. not investment advice", "current_price": 176.83, "recommendation": "HOLD", "thesis_bullets": [ "Invisalign remains the clear-aligner leader with strong gross margins.", "Recent revenue and EPS growth are muted, limiting rerating potential.", "Net cash and healthy free cash flow support downside resilience.", "Valuation looks reasonable, but upside needs clearer volume recovery.", "Modest margin improvement can offset only moderate top-line growth." ], "target_price_6m": 172, "target_price_12m": 184 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0b63df717e9c124b0069d73b288f2c81969a9b3c8357e603ae", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 36029, "createdAt": "2026-04-09T05:19:37.924Z", "usage": { "inputTokens": 2354, "outputTokens": 2041, "costUsd": 0.032694 } }, { "id": "cmnr12b4d01z4p65862v2380g", "runId": "cmnr12b4601z0p658790b6ncq", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"ALGN\",\n \"currency\": \"USD\",\n \"current_price\": 176.83,\n \"target_price_6m\": 185,\n \"target_price_12m\": 200,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Low single-digit growth projected after recent stagnation\",\n \"67% gross margins provide buffer against competition\",\n \"International expansion offers meaningful upside potential\",\n \"17x forward P/E reasonable if growth reaccelerates\",\n \"High valuation sensitivity to execution risks\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Clear aligner innovation cycle\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"US market saturation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"International adoption rates\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competitive intensity\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Consumer discretionary spend\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory approvals\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"New entrants eroding market share\",\n \"Prolonged slow growth in core markets\",\n \"Margin pressure from manufacturing costs\",\n \"Macro impact on elective procedures\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 7.5,\n \"ebit_margin_target\": 18,\n \"wacc\": 9.8,\n \"terminal_multiple\": 16\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 140,\n \"prob\": 0.3,\n \"notes\": \"Growth stays below 3% with margin contraction.\"\n },\n \"base\": {\n \"target_price\": 200,\n \"prob\": 0.45,\n \"notes\": \"Revenue CAGR hits 7.5% with stable margins.\"\n },\n \"bull\": {\n \"target_price\": 260,\n \"prob\": 0.25,\n \"notes\": \"Growth exceeds 12% driven by new markets and products.\"\n }\n },\n \"method_notes\": \"DCF using 7.5% revenue CAGR, 18% EBIT target, 9.8% WACC, 16x terminal. Prob-weighted scenario return ~10% supports BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "New entrants eroding market share", "Prolonged slow growth in core markets", "Margin pressure from manufacturing costs", "Macro impact on elective procedures" ], "ticker": "ALGN", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Revenue CAGR hits 7.5% with stable margins.", "target_price": 200 }, "bear": { "prob": 0.3, "notes": "Growth stays below 3% with margin contraction.", "target_price": 140 }, "bull": { "prob": 0.25, "notes": "Growth exceeds 12% driven by new markets and products.", "target_price": 260 } }, "confidence": 0.62, "assumptions": { "wacc": 9.8, "revenue_cagr_3y": 7.5, "terminal_multiple": 16, "ebit_margin_target": 18 }, "key_drivers": [ { "driver": "Clear aligner innovation cycle", "impact": "HIGH", "direction": "POS" }, { "driver": "US market saturation", "impact": "HIGH", "direction": "NEG" }, { "driver": "International adoption rates", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Competitive intensity", "impact": "MED", "direction": "NEG" }, { "driver": "Consumer discretionary spend", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory approvals", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using 7.5% revenue CAGR, 18% EBIT target, 9.8% WACC, 16x terminal. Prob-weighted scenario return ~10% supports BUY. Not investment advice.", "current_price": 176.83, "recommendation": "BUY", "thesis_bullets": [ "Low single-digit growth projected after recent stagnation", "67% gross margins provide buffer against competition", "International expansion offers meaningful upside potential", "17x forward P/E reasonable if growth reaccelerates", "High valuation sensitivity to execution risks" ], "target_price_6m": 185, "target_price_12m": 200 }, "errorsJson": { "attempts": [ { "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"ALGN\",\n \"currency\": \"USD\",\n \"current_price\": 176.83,\n \"target_price_6m\": 185,\n \"target_price_12m\": 195,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Low single-digit growth projected after recent stagnation\",\n \"67% gross margins provide buffer against competition\",\n \"International expansion offers meaningful upside potential\",\n \"17x forward P/E reasonable if growth reaccelerates\",\n \"High valuation sensitivity to execution risks\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Clear aligner innovation cycle\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"US market saturation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"International adoption rates\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competitive intensity\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Consumer discretionary spend\",\n \"impact\": …" } ], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "e6672fe9-4d56-9f69-a205-c99a0fb73bc1", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 16804, "createdAt": "2026-04-09T05:19:37.924Z", "usage": { "inputTokens": 3315, "outputTokens": 2989, "costUsd": 0.05478 } } ] } }